Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.

Also called NCT02270736

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 256 participants (enrolled count) (from the registry)
Sponsor
Merz Pharmaceuticals GmbH (from the registry)
Registry
  • NCT NCT02270736
  • EudraCT 2013-004532-30
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Georgia, Hungary, Poland, Russia, Serbia, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02270736. Randomized; double masking; primary purpose treatment. Start 2015-02-09 (actual); primary completion 2018-02-23 (actual). Results posted on 2021-01-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
Acronym
SIPEXI
Condition
Chronic Troublesome Sialorrhea
Condition
Cerebral Palsy
Condition
Stroke
Condition
Traumatic Brain Injury
Condition
Intellectual Disability
Intervention (Drug)
NT 201 Placebo
Intervention (Drug)
NT 201
Lead sponsor
Merz Pharmaceuticals GmbH (class: industry)

Record details

Record id
cardio:ct-nct02270736
Content hash
1388c4774833f67c2fffe54ba22776a9ae3602523751247471e0d65e6c76e7bc